Literature DB >> 15242422

Midbrain hypometabolism as early diagnostic sign for progressive supranuclear palsy.

M Mishina1, K Ishii, K Mitani, M Ohyama, M Yamazaki, K Ishiwata, M Senda, S Kobayashi, S Kitamura, Y Katayama.   

Abstract

OBJECTIVE: Progressive supranuclear palsy (PSP) is often misdiagnosed in early phase. The purpose of this study is to investigate the feature of [(18)F]fluoro-2-deoxy-d-glucose (FDG) positron emission tomography images for the early diagnosis of PSP.
METHODS: We studied 15 patients with PSP and 16 normal subjects. Using SPM99 and analysis of covariance to eliminate the effect of aging, the differences between PSP and normals were displayed as a statistical map. In the PSP, we also investigated the correlation with duration and with the subscores of Unified Parkinson's Disease Rating Scale.
RESULTS: The glucose metabolism of midbrain was significantly lower in PSP than in normals. However, correlation was not found between the metabolism of midbrain and clinical deterioration.
CONCLUSIONS: The statistical map clearly demonstrated the hypometabolism of midbrain in PSP, which is independent of the clinical deterioration. The hypometabolism of midbrain is one of the most promising sign for early diagnosis of PSP.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15242422     DOI: 10.1111/j.1600-0404.2004.00293.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  6 in total

Review 1.  Gray matter atrophy in progressive supranuclear palsy: meta-analysis of voxel-based morphometry studies.

Authors:  Hai Cun Shi; Jian Guo Zhong; Ping Lei Pan; Pei Rong Xiao; Yuan Shen; Li Juan Wu; Hua Liang Li; Yuan Ying Song; Gui Xiang He; Hong Ye Li
Journal:  Neurol Sci       Date:  2013-03-30       Impact factor: 3.307

2.  FDG-PET in pathologically confirmed spontaneous 4R-tauopathy variants.

Authors:  Nicholas Zalewski; Hugo Botha; Jennifer L Whitwell; Val Lowe; Dennis W Dickson; Keith A Josephs
Journal:  J Neurol       Date:  2014-02-04       Impact factor: 4.849

Review 3.  Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?

Authors:  Jennifer L Whitwell; Günter U Höglinger; Angelo Antonini; Yvette Bordelon; Adam L Boxer; Carlo Colosimo; Thilo van Eimeren; Lawrence I Golbe; Jan Kassubek; Carolin Kurz; Irene Litvan; Alexander Pantelyat; Gil Rabinovici; Gesine Respondek; Axel Rominger; James B Rowe; Maria Stamelou; Keith A Josephs
Journal:  Mov Disord       Date:  2017-05-13       Impact factor: 10.338

Review 4.  Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies.

Authors:  Maria Stamelou; Gesine Respondek; Nikolaos Giagkou; Jennifer L Whitwell; Gabor G Kovacs; Günter U Höglinger
Journal:  Nat Rev Neurol       Date:  2021-08-23       Impact factor: 42.937

Review 5.  Accumulation of Tau Protein, Metabolism and Perfusion-Application and Efficacy of Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) Imaging in the Examination of Progressive Supranuclear Palsy (PSP) and Corticobasal Syndrome (CBS).

Authors:  Piotr Alster; Natalia Katarzyna Madetko; Dariusz Mariusz Koziorowski; Leszek Królicki; Sławomir Budrewicz; Andrzej Friedman
Journal:  Front Neurol       Date:  2019-02-14       Impact factor: 4.003

6.  Cortical and Subcortical Dysmetabolism Are Dynamic Markers of Clinical Disability and Course in Anti-LGI1 Encephalitis.

Authors:  Eero Rissanen; Kelsey Carter; Steven Cicero; John Ficke; Marie Kijewski; Mi-Ae Park; Joseph Kijewski; Emily Stern; Tanuja Chitnis; David Silbersweig; Howard L Weiner; Chun K Kim; Jennifer Lyons; Joshua P Klein; Shamik Bhattacharyya; Tarun Singhal
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2022-01-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.